ClinicalTrials.gg
CompletedNCT01495858Morpheus/DPHUpdated Jun 8, 2015Results posted

Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain

A Phase 3 interventional study of Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) and Naproxen Sodium 440 mg (BAYH6689) in Pain, Postoperative, sponsored by Bayer. Completed at 2 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-08.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 13 studies testing naproxen in Pain, Postoperative — 2 open to participants now, 2 under way, 1 of them phase 3. Naproxen · Pain, Postoperative.

Enrollment
6th of 13
267 · median 200
Started
2011
with 1 other
Phase 3
5 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
5 of 13
Bayer

Among the 13 studies testing naproxen in Pain, Postoperative, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 5 in phase 3, and was the 4th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,240 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 13 studies testing naproxen in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About naproxen

Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 675 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 328 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing naproxen in Pain, Postoperative, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the efficacy and safety of a single oral dose of naproxen sodium 440 mg in combination with DPH (diphenhydramine) 25 mg in subjects with postsurgical dental pain and phase advanced sleep.

03

Conditions studied

  • Pain, Postoperative

Browse trials for

Keywords

  • Naproxen sodium
  • Diphenhydramine
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, ambulatory, male and female volunteers ages 12 and older
  • Scheduled to undergo surgical removal of a minimum of two third molars of which at least one has to be a mandibular third molar. The mandibular extraction(s) required by each subject must meet one of the following scenarios:

    • one full bony impaction
    • two partial bony impactions
    • one full bony impaction and one partial bony impaction
    • one full bony impaction and one soft tissue impaction
    • one full bony impaction and one erupted third molar. Two full bony mandibular impactions are not allowed. Maxillary third molars may be removed regardless of impaction level.
  • Have moderate to severe postoperative pain on the Categorical Pain Rating Scale and a score of >/= 50 mm on the 100-mm visual analog Pain Severity Rating Scale between 1600 hour and 1830 hour on the day of surgery
  • Female subjects of must be using a medically acceptable form of for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, Depo-Provera, or double-barrier and have a negative pregnancy test at Screening and prior to surgery. Female subjects of non-childbearing potential must be amenorrheic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy.

Exclusion criteria

Exclusion Criteria:

  • History of to naproxen, diphenhydramine, nonsteroidal anti-inflammatory drug (NSAIDS), tramadol, aspirin or any other antihistamine and similar pharmacological agents or components of the products
  • Evidence or history of (in the judgment of the investigator) hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic diseases, or within the last 5 years
  • Relevant concomitant disease such as asthma (exercise induced asthma is permitted), chronic sinusitis or nasal structural abnormalities causing greater than 50 percent obstruction (polyposis nasi, marked septal deviation) that can interfere with the conduct of the study in the judgment of the investigator
  • Current or past history of bleeding disorder(s)
  • Acute illness or local infection prior to surgery that can interfere with the conduct of the study in the judgment of the investigator
  • Chronic use of antihistamines defined as using 5 or more times a week for 2 or more consecutive weeks during the past 3 months
  • Positive alcohol breathalyzer test and positive urine drug test prior to surgery
  • Females who are pregnant or lactating
  • Chronic or severe sleep problems that do not respond to Over the Counter (OTC) medication and requires a prescription hypnotic or sedative
  • Habitually spends less than 6.5 hours in bed
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)

    Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)

  • Active comparator
    Naproxen Sodium 440 mg (BAYH6689)

    Drug: Naproxen Sodium 440 mg (BAYH6689)

  • Active comparator
    DPH 50 mg

    Drug: DPH 50 mg

Interventions

  • DrugNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)

    Drug page: NaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.

  • DrugNaproxenStudies of NaproxenNaproxen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.

  • DrugDPH 50 mg

    Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.

06

What researchers measure

Primary outcomes

  1. Wake Time After Sleep Onset (WASO) Measured by Actigraphy

    WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

  2. Sleep Latency Measured by Actigraphy

    Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

Secondary outcomes

  1. Total Sleep Time Measured by Actigraphy

    Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

  2. Sleep Efficiency Measured by Actigraphy

    Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

    Time frame: Up to 10 hours

  3. Global Assessment of Investigational Product as a Sleep Aid

    The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).

    Time frame: Up to 10 hours

  4. Karolinska Sleep Diary - Sleep Quality

    Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)

    Time frame: Up to 10 hours

  5. Karolinska Sleep Diary - Calmness of Sleep

    Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)

    Time frame: Up to 10 hours

  6. Karolinska Sleep Diary - Easiness to Fall Asleep

    Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)

    Time frame: Up to 10 hours

  7. Karolinska Sleep Diary - Premature Awakening

    Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)

    Time frame: Up to 10 hours

  8. Karolinska Sleep Diary - Ease of Awakening

    Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)

    Time frame: Up to 10 hours

  9. Karolinska Sleep Diary - Well Rested

    Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)

    Time frame: Up to 10 hours

  10. Karolinska Sleep Diary - Sufficient Sleep

    Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)

    Time frame: Up to 10 hours

  11. Subjective Sleep Questionnaire - Quality of Your Sleep Last Night

    Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.

    Time frame: Up to 10 hours

  12. Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night

    Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)

    Time frame: Up to 10 hours

  13. Subjective Sleep Questionnaire - Time to Fall Asleep Last Night

    Subjects responded to Estimate of how long it took to fall asleep (minutes)

    Time frame: Up to 10 hours

  14. Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed

    Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)

    Time frame: Up to 10 hours

  15. Change From Baseline in Pain Intensity

    Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain

    Time frame: Baseline and up to 10 hours

  16. Overall Rating of Pain Relief

    The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).

    Time frame: Up to 10 hours

  17. Time to Rescue Medication

    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

    Time frame: Up to 10 hours

  18. Cumulative Proportion of Participants Taking Rescue Medication by Hour

    If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

    Time frame: Up to 10 hours

  19. Global Assessment of Investigational Product as a Pain Reliever

    The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).

    Time frame: Up to 10 hours

Other outcomes

  1. Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2

    Time frame: Baseline and day 2

  2. Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2

    Time frame: Baseline and Day 2

  3. Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2

    Time frame: Baseline and day 2

  4. Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2

    Time frame: Baseline and day 2

07

Results

Posted Jun 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Started10710654
Completed10710654
Not completed000

Outcome measures

PrimaryWake Time After Sleep Onset (WASO) Measured by Actigraphy

WASO was defined as Total wake time (in minutes) after sleep onset during the 10 hours in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Wake Time After Sleep Onset (WASO) Measured by Actigraphy
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Wake Time After Sleep Onset (WASO) Measured by Actigraphy155.25 (121.57 to 188.93)180.08 (146.36 to 213.80)364.83 (317.52 to 412.15)
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.3047
PrimarySleep Latency Measured by Actigraphy

Sleep latency was defined as the time to sleep onset from the time of dosing as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Median · Minutes
Sleep Latency Measured by Actigraphy
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Sleep Latency Measured by Actigraphy23.50 (18.00 to 28.00)16.75 (13.50 to 25.00)27.50 (16.00 to 36.50)
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Log Rank · p = 0.1677
SecondaryTotal Sleep Time Measured by Actigraphy

Total time spent sleeping (not to exceed 600 minutes) during the in-bed period as measured by actigraphy. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Minutes
Total Sleep Time Measured by Actigraphy
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Total Sleep Time Measured by Actigraphy418.66 (385.05 to 452.28)392.38 (358.72 to 426.03)206.61 (159.39 to 253.84)
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.2764
SecondarySleep Efficiency Measured by Actigraphy

Sleep efficiency was calculated as (total sleep time/total time in-bed time) × 100; total in-bed time was fixed at 10 hours. Actigraphy is a non-intrusive tool that measures an individual's movement during sleep. Actigraphy was used to obtain data in discriminating between sleep and wake states in the subjects.

Time frame:
Up to 10 hours
Reported as:
Least squares mean · Percent of sleep time during in-bed time
Sleep Efficiency Measured by Actigraphy
Percent of sleep time during in-bed timeNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Sleep Efficiency Measured by Actigraphy69.777 (64.175 to 75.380)65.396 (59.787 to 71.006)34.436 (26.566 to 42.306)
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.2764
SecondaryGlobal Assessment of Investigational Product as a Sleep Aid

The Global Assessment of Investigational Product as a Sleep-Aid was rated using a 5-point categorical scale for which the potential response was poor (0), fair, (1), good (2), very good (3), or excellent (4).

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Global Assessment of Investigational Product as a Sleep Aid
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
0 = Poor2131
1 = Fair12247
2 = Good37242
3 = Very good23138
4 = Excellent1151
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · Cochran-Mantel-Haenszel · p = <0.0001
SecondaryKarolinska Sleep Diary - Sleep Quality

Subjects responded to the following question: How was your sleep? very poor (1); rather poor (2); neither poor nor good (3); rather good (4); very good (5)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Sleep Quality
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Very poor139
2 = Rather poor122211
3 = Neither poor nor good33319
4 = Rather good473612
5 = Very good9103
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0004
SecondaryKarolinska Sleep Diary - Calmness of Sleep

Subjects responded to the following question: How calm was your sleep? very restless (1); rather restless (2); neither restless nor calm (3); rather calm (4); very calm (5)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Calmness of Sleep
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Very restless135
2 = Rather restless262917
3 = Neither restless nor calm18245
4 = Rather calm484213
5 = Very calm944
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0145
SecondaryKarolinska Sleep Diary - Easiness to Fall Asleep

Subjects responded to the following question: How easy was it to fall asleep? very difficult (1); rather difficult (2); neither difficult nor easy (3); rather easy (4); very easy (5)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Easiness to Fall Asleep
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Very difficult389
2 = Rather difficult29336
3 = Neither difficult nor easy222714
4 = Rather easy362312
5 = Very easy12113
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = >0.05
SecondaryKarolinska Sleep Diary - Premature Awakening

Subjects responded to the following question : Premature awakening? woke up much too early (1); woke up somewhat too early (2); no (3)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Premature Awakening
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Woke up much too early243121
2 = Woke up somewhat too early455211
3 = No331912
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0387
SecondaryKarolinska Sleep Diary - Ease of Awakening

Subjects responded to the following question: Ease of awakening? (1) very difficult; (2) rather difficult; (3) neither difficult nor easy; (4) rather easy; very easy (5)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Ease of Awakening
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Very difficult030
2 = Rather difficult102
3 = Neither difficult nor easy17165
4 = Rather easy565314
5 = Very easy283023
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0305
SecondaryKarolinska Sleep Diary - Well Rested

Subjects responded to the following question: Well Rested? not rested at all (1); somewhat unrested (2); completely rested (3)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Well Rested
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = Not rested at all7913
2 = Somewhat unrested535517
3 = Completely rested423814
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0176
SecondaryKarolinska Sleep Diary - Sufficient Sleep

Subjects responded to the following question: Did you get enough (sufficient) sleep? no, definitely too little (1); no, much too little (2); no, somewhat too little (3); yes, almost enough (4); yes, definitely enough (5)

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Karolinska Sleep Diary - Sufficient Sleep
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
1 = No, definitely too little21013
2 = No, much too little8106
3 = No, somewhat too little18278
4 = Yes, almost enough523411
5 = Yes, definitely enough22216
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = <0.0001
SecondarySubjective Sleep Questionnaire - Quality of Your Sleep Last Night

Subject evaluated sleep quality on a 10-point scale, where 1 was poor and 10 was excellent.

Time frame:
Up to 10 hours
Reported as:
Mean · Scores on a scale
Subjective Sleep Questionnaire - Quality of Your Sleep Last Night
Scores on a scaleNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Subjective Sleep Questionnaire - Quality of Your Sleep Last Night6.5 ± 1.955.8 ± 2.114.9 ± 3.04
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = 0.0036
SecondarySubjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night

Subjects responded to Refreshing nature of sleep (10-point scale, where 1 was not refreshing and 10 was very refreshing)

Time frame:
Up to 10 hours
Reported as:
Mean · Scores on a scale
Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night
Scores on a scaleNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Subjective Sleep Questionnaire - Refreshing Nature of Your Sleep Last Night6.6 ± 2.155.7 ± 2.204.6 ± 2.85
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = <0.0001
SecondarySubjective Sleep Questionnaire - Time to Fall Asleep Last Night

Subjects responded to Estimate of how long it took to fall asleep (minutes)

Time frame:
Up to 10 hours
Reported as:
Mean · Minutes
Subjective Sleep Questionnaire - Time to Fall Asleep Last Night
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Subjective Sleep Questionnaire - Time to Fall Asleep Last Night39.5 ± 36.6340.2 ± 38.1040.0 ± 42.66
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = >0.05
SecondarySubjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed

Subjects responded to Estimate of the amount of time the subject was awake from the time he or she fell asleep until the time he or she got out of bed (hours and minutes)

Time frame:
Up to 10 hours
Reported as:
Mean · Minutes
Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Subjective Sleep Questionnaire - Number of Minutes You Think That You Were Awake From the Time You Fell Asleep Until the Time You Got Out of Bed111.1 ± 121.86144.8 ± 125.5898.4 ± 89.71
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs DPH 50 mg · Cochran-Mantel-Haenszel · p = >0.05
SecondaryChange From Baseline in Pain Intensity

Pain Severity was collected on a 4-point categorical scale: 0=no pain, 1=mild pain, 2=moderate pain, 4=severe pain

Time frame:
Baseline and up to 10 hours
Reported as:
Mean · Scores on a scale
Change From Baseline in Pain Intensity
Scores on a scaleNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Change From Baseline in Pain Intensity2.4 ± 0.482.4 ± 0.492.5 ± 0.50
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.4519
SecondaryOverall Rating of Pain Relief

The Pain Relief Rating Scale was a 5-point categorical scale which included the following possible responses to the request to finish statement "Overall, the relief from my starting pain was": no relief (0); a little relief (1); some relief (2); a lot of relief (3); complete relief (4).

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Overall Rating of Pain Relief
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
0 = No relief243035
1 = A little relief534
2 = Some relief10155
3 = A lot of relief47378
4 = Complete relief21212
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · ANCOVA · p = 0.3707
SecondaryTime to Rescue Medication

If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

Time frame:
Up to 10 hours
Reported as:
Median · Minutes
Time to Rescue Medication
MinutesNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Time to Rescue MedicationNA (NA to NA)NA (NA to NA)146.50 (118.00 to 314.00)
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · Log Rank · p = >0.05
SecondaryCumulative Proportion of Participants Taking Rescue Medication by Hour

If rescue medication was taken by a subject for pain, then the time of rescue medication administration was recorded

Time frame:
Up to 10 hours
Reported as:
Number · participants
Cumulative Proportion of Participants Taking Rescue Medication by Hour
participantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
≤ 60 minutes010
≤ 120 minutes91221
≤ 180 minutes141329
≤ 240 minutes151732
≤ 300 minutes162333
≤ 360 minutes172534
≤ 420 minutes212635
≤ 480 minutes222835
≤ 540 minutes243035
≤ 600 minutes243035
SecondaryGlobal Assessment of Investigational Product as a Pain Reliever

The Global Assessment of Investigational Product as a Pain Reliever was a 5- point categorical scale which included the following possible responses: poor (0); fair (1); good (2); very good (3); excellent (4).

Time frame:
Up to 10 hours
Reported as:
Number · Participants
Global Assessment of Investigational Product as a Pain Reliever
ParticipantsNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
0 = Poor111
1 = Fair435
2 = Good22253
3 = Very good40389
4 = Excellent18121
Statistical analysis
  • Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111) vs Naproxen Sodium 440 mg (BAYH6689) · Cochran-Mantel-Haenszel · p = 0.3765
Other pre-specifiedVital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2
Time frame:
Baseline and day 2
Reported as:
Mean · mmHg
Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2
mmHgNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Vital Signs: Mean Change From Baseline in Systolic Blood Pressure at Day 2-1.3 ± 12.65-0.6 ± 13.512.2 ± 11.77
Other pre-specifiedVital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2
Time frame:
Baseline and Day 2
Reported as:
Mean · mmHg
Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 2
mmHgNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Vital Signs: Mean Change From Baseline in Diastolic Blood Pressure at Day 20.7 ± 10.58-0.2 ± 8.422.1 ± 8.83
Other pre-specifiedVital Signs: Mean Change From Baseline in Pulse Rate at Day 2
Time frame:
Baseline and day 2
Reported as:
Mean · Beats/min
Vital Signs: Mean Change From Baseline in Pulse Rate at Day 2
Beats/minNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Vital Signs: Mean Change From Baseline in Pulse Rate at Day 21.0 ± 10.57-0.1 ± 11.944.7 ± 12.65
Other pre-specifiedVital Signs: Mean Change From Baseline in Respiratory Rate at Day 2
Time frame:
Baseline and day 2
Reported as:
Mean · Breaths/min
Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2
Breaths/minNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
Vital Signs: Mean Change From Baseline in Respiratory Rate at Day 2-1.4 ± 3.12-1.2 ± 2.97-0.3 ± 2.70

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected from the date of the first dose of study drug in the treatment period for 2 days, or for 30 days after the last study drug administration if they were serious adverse events (SAEs).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)—0/107 (0%)21/107 (19.6%)
Naproxen Sodium 440 mg (BAYH6689)—0/106 (0%)14/106 (13.2%)
DPH 50 mg—0/54 (0%)17/54 (31.5%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventNaproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mg
HeadacheNervous system disorders6/1073/10610/54
DizzinessNervous system disorders9/1079/1062/54
NauseaGastrointestinal disorders6/1074/1062/54
Cold sweatSkin and subcutaneous tissue disorders3/1070/1061/54
Vision blurredEye disorders1/1070/1061/54
VomitingGastrointestinal disorders1/1070/1061/54
Feeling jitteryGeneral disorders0/1070/1061/54
Procedural complicationInjury, poisoning and procedural complications0/1070/1061/54
Blood pressure increasedInvestigations0/1070/1061/54
PollakiuriaRenal and urinary disorders0/1070/1061/54

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mgTotal
Mean21.4 ± 5.5521.3 ± 5.2720.8 ± 4.6421.2 ± 5.25
Sex: Female, Male
Sex: Female, Male(Participants)Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mgTotal
Female726437173
Male35421794
Baseline Categorical Pain Rating Scale
Baseline Categorical Pain Rating Scale(Participants)Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)Naproxen Sodium 440 mg (BAYH6689)DPH 50 mgTotal
No pain0000
Mild pain0000
Moderate pain696328160
Severe pain384326107
08

Study locations

2 sites
  • Austin, Texas 78744, United States
  • Salt Lake City, Utah 84106, United States
09

References and documents

Publications

  • Cooper S, Laurora I, Wang Y, Venkataraman P, An R, Roth T. Efficacy and tolerability studies evaluating a sleep aid and analgesic combination of naproxen sodium and diphenhydramine in the dental impaction pain model in subjects with induced transient insomnia. Int J Clin Pract. 2015 Oct;69(10):1149-58. doi: 10.1111/ijcp.12669. Epub 2015 May 21. PubMed 25996289 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 4 months after primary completion. A results delay was requested in May 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2011
First posted
Dec 20, 2011
Start
Dec 2011
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results delay requested
May 30, 2012
Results first posted
Jun 17, 2014
Last update
Jun 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01495858
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 20, 2011
Start date
Dec 2011
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Jun 17, 2014
Last update
Jun 8, 2015

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naproxen

Start the discussion